Balance Sheet

v3.19.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash $ 4,812,697 $ 279,772
Accounts receivable, net 8,000
Prepaid expenses 61,475 31,458
Total current assets 4,874,172 319,230
Property and equipment, net 106,461 44,369
Right to use assets, net 266,647
Other assets:    
Patents 15,200 15,200
Intellectual property, net 236,000 236,000
Deposits, long term 13,422 13,422
Total other assets 264,622 264,622
Total assets 5,511,902 628,221
Current liabilities:    
Accounts payable and accrued expenses, including related party payables of $196,642 and $32,318, respectively 1,536,271 1,554,652
Deferred revenue, short term 131,434 209,474
Lease liability, short term 43,574
Convertible notes payable, net of debt discount of $0 and $656,231 4,160,000 3,503,769
Notes payable, net of debt discounts of $19,428 and $127,419 505,572 672,581
Notes payable, related party 186,590 186,590
Total current liabilities 6,563,441 6,127,066
Long term debt:    
Royalty obligation - net of discount of $7,055,866 and $0 (related party - $833,177, net of discount of $3,527,933 and $0) 1,666,234
Deferred revenue, long term 168,563 207,523
Total liabilities 259,790
Commitments and contingencies 8,658,028 6,334,589
Deficit:    
Common stock, $0.001 par value; 750,000,000 shares authorized, 3,057,848 and 2,597,347 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively 3,058 2,597
Common stock subscribed 100,000 100,000
Additional paid in capital 55,789,574 49,418,356
Accumulated deficit (58,986,432) (55,176,450)
Total deficit attributable to BioCorRx, Inc. (3,072,184) (5,633,881)
Non-controlling interest (73,942) (72,487)
Total deficit (3,146,126) (5,706,368)
Total liabilities and deficit 5,511,902 628,221
Series A Preferred Stock [Member]    
Deficit:    
Preferred stock value 16,000 16,000
Series B Preferred Stock [Member]    
Deficit:    
Preferred stock value $ 5,616 $ 5,616

Source